Sanofi can’t even buy a break now, as ri­val No­vo speeds ahead on di­a­betes show­down

Things are just not go­ing Sanofi’s way. Late last week, just a cou­ple of days be­fore Pfiz­er scooped out Medi­va­tion af­ter slam­ming the French phar­ma’s bid to the side­lines, Sanofi had to con­cede that its ap­pli­ca­tion for a Lan­tus-plus-lixise­n­atide com­bo has been de­layed. The FDA now plans to make a de­ci­sion in No­vem­ber so it can take ex­tra time to con­sid­er the fresh da­ta it de­mand­ed to see.

Sanofi’s loss is No­vo’s gain. The Dan­ish phar­ma com­pa­ny looks to be on the in­side track at the FDA af­ter win­ning a unan­i­mous vote at an agency pan­el re­view for Xul­to­phy, its ri­val com­bi­na­tion of Tre­si­ba with its GLP-1 block­buster Vic­toza.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER